Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calistoga Pharmaceuticals, a company that develops isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases,has appointed Langdon Miller, as a new executive vice president of research & development of the company.
Subscribe to our email newsletter
Most recently, Dr Miller has served as a chief medical officer of PTC Therapeutics and led the strategic design and implementation of development activities for the company’s clinical-stage compounds.
Prior to PTC, Dr Miller has served as vice president of global oncology clinical research at Pharmacia Corporation.
Carol Gallagher, president and CEO of Calistoga Pharma, said: “We are very pleased to have Dr Miller join our team to lead our full development efforts for CAL-101 and advance our isoform-selective PI3K inhibitor pipeline.”
Dr Miller said: “The team at Calistoga Pharmaceuticals has made great progress in advancing a first-in-class pipeline of isoform-selective PI3K inhibitors. The clinical data are very encouraging, and I look forward to leading the company’s efforts to advance these candidates as potential novel treatments for patients with cancer and inflammatory diseases.”